CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Bullfrog AI Holdings, Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Bullfrog AI Holdings, Inc.
323 Ellington Blvd, Unit 317
Phone: (240) 658-6710p:240 658-6710 GAITHERSBURG, MD  20878  United States Ticker: BFRGBFRG

Business Summary
Bullfrog AI Holdings, Inc. is a technology-enabled drug development company. The Company is focused specifically on advanced artificial intelligence / machine learning (AI/ML) analysis of complex data in the advancement of medicine. The Company’s platform technology, bfLEAP, is an analytical AI/ML platform that is a potentially disruptive tool for the analysis of pre-clinical and/or clinical data sets, such as the robust pre-clinical and clinical trial data sets being generated in translational research and development and clinical trial settings. The platform can capture the genetic and physical characteristics of patients in an unbiased manner and contextualize them against other disparate data sources from patients. Its siRNA targets Beta2-spectrin in the treatment of human diseases, such as hepatocellular carcinoma (HCC), obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis. Mebendazole is focused on targeting Glioblastoma.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
12/31/202312/31/2023YesYes---

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Chief Executive Officer, Director VininderSingh 54 8/1/2017 8/1/2017
Chief Financial Officer Dane R.Saglio 65 9/1/2021 9/1/2021
Vice President - Artificial Intelligence EnriqueGarca-Rivera 7/11/2023 7/11/2023
4 additional Officers and Directors records available in full report.

Business Names
Business Name
bfLEAP
BFRG
Bullfrog AI Management, LLC
BullFrog AI, Inc
BullFrog Management, LLC

General Information
Number of Employees: 4 (As of 2/10/2024)
Outstanding Shares: 7,850,550 (As of 3/27/2024)
Shareholders: 17
Stock Exchange: NASD
Federal Tax Id: 844786155
Fax Number: (302) 531-3150


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, April 26, 2024